Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Has chronic HCV genotype 1 infection~* Is treatment-experienced~* For the non-cirrhotic population, has had a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma; for the cirrhotic population, has had a liver biopsy with evidence of cirrhosis and without evidence of hepatocellular carcinoma.~Exclusion criteria:~* Has not tolerated previous course peg-IFN and RBV~* Is unlikely to tolerate at least 24 weeks of continuous therapy with Peg-IFN and RBV~* Is co-infected with Human Immunodeficiency Virus (HIV) and/or hepatitis B~* Consumes excessive amounts of alcohol~* Has a history of drug or alcohol abuse~* If female, participant is pregnant or breastfeeding~* Has been in a clinical trail with an investigational drug in the last 30 days~* Has used IFN/Peg-IFN and RBV in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 24-wk Vaniprevir 600 mg + Peg-IFN/RBV (Type: EXPERIMENTAL): Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
- 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV (Type: EXPERIMENTAL): Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
- 48-wk Vaniprevir 300 mg + Peg-IFN/RBV (Type: EXPERIMENTAL): Vaniprevir 300 mg (total daily dose, taken once daily \[q.d.\]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
- 48-wk Vaniprevir 600 mg + Peg-IFN/RBV (Type: EXPERIMENTAL): Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
- 48-wk PBO + Peg-IFN/RBV (Type: PLACEBO_COMPARATOR): PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).